Phase II clinical study of high-dose toremifene in patients with advanced breast cancer

J Steroid Biochem. 1990 Jun 22;36(3):237-8. doi: 10.1016/0022-4731(90)90015-k.

Abstract

Thirteen postmenopausal women with advanced local or metastatic breast cancer were treated with the antiestrogen toremifene at a daily dose of 200 mg. All patients had failed previous treatment with different types of endocrine therapy and/or cytotoxic drugs. Objective response was only seen in one patient. Treatment was usually well tolerated but in three cases the drug had to be withdrawn due to side effects.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / drug therapy*
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Evaluation
  • Estrogen Antagonists / administration & dosage
  • Estrogen Antagonists / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Tamoxifen / administration & dosage
  • Tamoxifen / analogs & derivatives*
  • Tamoxifen / therapeutic use
  • Toremifene

Substances

  • Estrogen Antagonists
  • Tamoxifen
  • Toremifene